Neue Studien zeigen Erfahrungen und Einstellungen in der Obstetrik zur Benutzung nicht-invasiver pränataler Testverfahren in der Praxis auf

PDF-Datei herunterladen

San Jose, Calif., April 2, 2013 – Two new studies in Prenatal Diagnosis demonstrate the favorable
experience and increasing interest on the part of U.S. obstetrician-gynecologists (OB-GYNs) to implement
non-invasive prenatal testing (NIPT) into the clinical practice setting for screening of pregnant women for
common genetic conditions.

In the first study, entitled “Clinical experience of noninvasive prenatal testing with cell-free DNA for fetal
trisomies 21, 18, and 13, in a general screening population”, research was conducted among pregnant
women who underwent prenatal screening for fetal trisomy from July 30, 2012, to December 1, 2012.
NIPT was offered to all patients presenting for prenatal care. Authors concluded that NIPT has distinct
advantages over current screening methods for risk assessment of fetal trisomies 21, 18, and 13 in
general pregnant populations. For further details on the study, please visit:

“The incorporation of NIPT into our everyday clinical practice has been very successful. This new
screening test is more accurate, simpler to administer, and patients are readily embracing it. The
technology has clear benefits for any pregnant woman, and affordability is likely the main barrier to NIPT
being used more broadly,” explained Dr. Genevieve Fairbrother, OB-GYN and chief of staff at Northside
Hospital in Atlanta, GA, as well as lead author of the Prenatal Diagnosis publication cited above.

To understand overall views about NIPT across the general obstetrician population, a second study
entitled “Non-invasive prenatal testing with cell-free DNA: U.S. physician attitudes toward implementation
in clinical practice”, surveyed 101 clinicians. The survey assessed awareness and future plans to adopt
utilization of NIPT in clinical practice. Investigators found that OB-GYNs plan to increase their utilization of
NIPT and expect that the majority of both high-risk and average-risk patients will be offered NIPT as an
option. For more information on the study, please visit:

“This survey indicates that among U.S. OB-GYNs, awareness and use of NIPT is high despite having
been introduced recently. This interest in incorporating safer and more accurate screening into prenatal
practice underscores the potential for NIPT to significantly improve the prenatal diagnosis experience for
millions of pregnant women,” commented Dr. Thomas Musci, vice president of clinical and medical affairs
at Ariosa Diagnostics.